塞德斯医疗（Celldex Therapeutics）已顺利完成其创新药物Barzolvolimab针对慢性自发性荨麻疹的两项全球III期临床研究——Embarq-Csu1与Embarq-Csu2的患者招募工作。这一重要进展标志着该疗法在验证其疗效与安全性的关键阶段迈出了坚实一步，为后续数据分析和监管申报奠定了坚实基础。
塞德斯医疗（Celldex Therapeutics）已顺利完成其创新药物Barzolvolimab针对慢性自发性荨麻疹的两项全球III期临床研究——Embarq-Csu1与Embarq-Csu2的患者招募工作。这一重要进展标志着该疗法在验证其疗效与安全性的关键阶段迈出了坚实一步，为后续数据分析和监管申报奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.